These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8640675)

  • 1. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
    Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
    Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
    Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
    Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
    Cuatrecasas M; Catasus L; Palacios J; Prat J
    Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
    Kuwata T; Kitagawa M; Takemura T; Hirokawa K
    Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
    Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
    Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
    Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
    Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
    J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
    Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
    Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
    Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
    Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
    Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
    Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
    Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.